Thought it interesting to start a new thread tracking two great little Aussie Biotechs, although they are very different in the amount of short selling - it's a good way to show the impact constant shorting and manipulation is having on the Clinuvel valuation. Shorters with their fake liquidity and manipulations have brought the valuation of Clinuvel to less than Botanix (when cash is taken out) - more than 110000 new fake shares in just the last 3 days ASIC data is available. Botanix is a good Aussie Biotech but they don't even have 1% of the revenue that Clinuvel has, and they do not have a chance at reaching the same heights as CUV could well do with their blockbuster Vitiligo phase 3 or a tanning photocosmetic. Take out cash and amazingly Botanix is worth more and interestingly they even completed THREE capital raising during the year. Once again, what is happening with the three investor experts on three continents that Clinuvel employs? Share buyback? Maybe now at these 5 year lows in price they will attract some big players. Clinuvel the most shorted Biotech stock with their $1 Million profits each week and growing (before tax) and explosive pipeline, my opinion is a takeover is behind this, analyst price targets are ~100% higher than current pricing - and mostly just based on EPP. Oh and Botanix has zero percent, 0.00%, open shorts compared to 6.28% at heavily shorted Clinuvel - so I would guess the hedge fund shorting/controlling CUV is long on Botanix. Every shorted share of Clinuvel designed to make the share price fall and keep it down, every piece of positive news is met with shorting and a share price fall - very weird the Clinuvel mathematician should look for a correlation here - don't most companies go up on positive news and ever increasing financial performance? Regardless, Clinuvel is in the best position they have ever been in with an absolute monopoly and peerless financial performance.
Botanix: Revenue FY2024: $0.6 Million Net Loss for FY2024: -$13.8M (loss) CASH ON HAND $79 MILLION (would be less now) Market cap. 632 Million AUD SHORTING 0.0%
Clinuvel (CUV) Revenue FY2024: $95 Million Net Profit after tax FY2024: $35.6M (profit) CASH ON HAND $184 MILLION (probably ~ $190 Million + by now) Market cap. 646 Million AUD SHORTING 6.28%
All IMO DYOR
CUV Price at posting:
$12.92 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)